James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

May 30, 2026 by InsiderTrades.com

Key Points

United Therapeutics CFO James Edgemond sold 10,000 shares on May 28 at an average price of $565.63, totaling about $5.66 million. After the sale, he still held 18,876 shares, cutting his ownership by 34.63%.
Edgemond has been a consistent seller this month, with multiple 10,000-share sales in late April and throughout May. The repeated insider selling may weigh on investor sentiment, especially alongside other executive sales.
United Therapeutics shares opened at $556.82, below recent trading levels but still near their 50-day average of $566.51 and well above the 200-day average of $515.84. The stock has also been volatile over the past year, ranging from $272.12 to $609.35.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00. Following the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $10,676,831.88. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

James Edgemond also recently made the following trade(s):

On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00.
On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.
On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total transaction of $5,769,300.00.
On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total value of $209,609.40.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $556.82 on Friday. The business has a 50-day moving average of $566.51 and a 200 day moving average of $515.84. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market capitalization of $23.64 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.

Liquidia: Court victory the awakening of an industry giant?

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

Institutional Trading of United Therapeutics

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Several institutional investors have recently made changes to their positions in UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth about $31,000. International Assets Investment Management LLC grew its holdings in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America raised their price target on United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $619.42.

Read Our Latest Stock Report on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.